IB Options Brief: Eli Lilly Co. (LLY)
LLY – Eli Lilly Co.
Shares in Eli Lilly, currently up better than 3.5% at $52.60, are rallying for a second consecutive day on encouraging results from a study of the drug maker’s experimental Alzheimer’s treatment. The stock is trading at the highest level since April 2008, and it looks like some options traders are positioning for shares in the name to extend gains, potentially taking out those five-year highs, by the start of the New Year.
Bullish strategists looked to the Jan. 2013 expiry options, exchanging nearly 5,000 calls at the $52.5 strike by 11:40 a.m. ET, versus previously existing open interest of 500 contracts. Traders appear to have purchased most of the $52.5 call options for an average premium of $1.55 apiece this morning and may profit at expiration next year in the event that LLY shares exceed the average breakeven price of $54.05.
Call buyers took to the Jan. 2013 $55 and $60 strike calls, as well. The $60 strike call has changed hands more than 1,500 times this morning against open interest of 340 contracts, with most of the volume purchased at an average premium of $0.10 each. Traders long the $60 calls make money in the event that Lilly’s shares surge 14% over the current price of $52.60 to top $60.10 by expiration in January. Eli Lilly’s third-quarter earnings report is just around the corner, scheduled for release on October 24th prior to the opening bell.
Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither Interactive Brokers LLC nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither IB nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance is not necessarily indicative of future results.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
View Caitlin Duffy's post archive >